New England Journal of Medicine July 13, 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter et al.

Source: View publication →

Bottom Line

The addition of pertuzumab to adjuvant trastuzumab and chemotherapy significantly improved invasive-disease-free survival in patients with early HER2-positive breast cancer, with the benefit primarily restricted to the node-positive subgroup.

Key Findings

1. The addition of pertuzumab to trastuzumab and chemotherapy significantly reduced the risk of invasive-disease events (HR 0.81; 95% CI 0.66 to 1.00; P=0.045) [1.1].

2. At 3 years, the estimated invasive-disease-free survival (IDFS) rate was 94.1% in the pertuzumab group versus 93.2% in the placebo group, representing a modest absolute improvement of 0.9%.

3. In the high-risk node-positive cohort, pertuzumab significantly improved 3-year IDFS (92.0% vs. 90.2%; HR 0.77; 95% CI 0.62 to 0.96; P=0.02).

4. In the node-negative cohort, pertuzumab did not improve 3-year IDFS (97.5% vs. 98.4%; HR 1.13; 95% CI 0.68 to 1.86; P=0.64).

5. Grade 3 or higher diarrhea occurred almost exclusively during the chemotherapy phase and was significantly more common in the pertuzumab group (9.8%) compared to the placebo group (3.7%).

6. Severe cardiac events, such as heart failure and cardiac death, were infrequent and comparable between the two groups, confirming the cardiac safety of dual HER2 blockade.

Study Design

Design

RCT

Double-Blind

Sample

4,805

Patients

Duration

45.4 mo

Median

Setting

Multicenter, global

Population Patients with operable, HER2-positive, early breast cancer (initially all-comers, later restricted to node-positive or high-risk node-negative)

Intervention Adjuvant pertuzumab + trastuzumab + standard chemotherapy for 1 year

Comparator Placebo + trastuzumab + standard chemotherapy for 1 year

Outcome Invasive-disease-free survival (IDFS)

Study Limitations

• The absolute benefit in the overall intent-to-treat population was very small (0.9% at 3 years), increasing the risk of overtreatment, financial toxicity, and adverse effects for lower-risk patients [1.8].

• The baseline event rate was lower than the statistically predicted 89.2% in the placebo group, even after a mid-trial protocol amendment restricted enrollment to node-positive or high-risk node-negative patients.

• At the time of the primary analysis, the median follow-up was only 45.4 months, which is relatively short for evaluating long-term survival outcomes in a population where 64% had hormone receptor-positive disease prone to late recurrences.

• No overall survival (OS) benefit was observed at the primary analysis.

Clinical Significance

The APHINITY trial established dual HER2-targeted therapy (pertuzumab plus trastuzumab) alongside chemotherapy as a new standard of care for the adjuvant treatment of high-risk, node-positive early HER2-positive breast cancer. However, the trial's lack of benefit in node-negative patients and the very small absolute difference across the overall population underscored the necessity of careful patient selection to avoid unnecessary toxicity and limit healthcare expenditures. In clinical practice, these results strictly limited the routine use of adjuvant pertuzumab to patients with node-positive disease.

Historical Context

Following the paradigm-shifting success of 1 year of adjuvant trastuzumab in early HER2-positive breast cancer (demonstrated by HERA, NSABP B-31, and NCCTG N9831), researchers sought to further reduce recurrence rates. Pertuzumab, a monoclonal antibody that binds a different HER2 epitope to prevent HER2/HER3 dimerization, had previously demonstrated a dramatic 15.7-month overall survival benefit when added to trastuzumab and docetaxel in the metastatic setting (CLEOPATRA) and significantly increased pathological complete response rates in the neoadjuvant setting (NeoSphere). APHINITY was launched as the definitive Phase III confirmatory trial to evaluate whether this dual blockade could translate to improved cure rates in the adjuvant setting.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How do the mechanisms of action of trastuzumab and pertuzumab differ, and why is their combination synergistic in treating HER2-positive breast cancer?

Key Response

Trastuzumab binds to subdomain IV of the HER2 extracellular domain, inhibiting ligand-independent signaling and flagging the cell for ADCC. Pertuzumab binds to subdomain II, sterically hindering ligand-dependent HER2-HER3 dimerization, which is a potent driver of tumor growth. Together, they provide comprehensive dual blockade of the HER2 signaling pathway.

Resident

Based on the APHINITY trial results, how should you stratify a patient with early-stage HER2-positive breast cancer to decide whether to add adjuvant pertuzumab to their trastuzumab and chemotherapy regimen?

Key Response

The trial demonstrated that the iDFS benefit of adding pertuzumab was primarily driven by the node-positive subgroup. Therefore, residents should recognize that adjuvant pertuzumab is indicated for patients with high-risk features, specifically node-positive disease, while node-negative patients may safely be spared the added toxicity like severe diarrhea and cost.

Fellow

The APHINITY trial reported a statistically significant improvement in iDFS, but the absolute benefit at 3 years was only 0.9 percent in the overall population and 1.8 percent in the node-positive subgroup. How do you integrate these modest absolute gains with known toxicities when counseling a high-risk patient, particularly in the context of the KATHERINE trial data?

Key Response

Fellows must grapple with the clinical significance of small absolute benefits in highly effective baseline regimens. While APHINITY supports escalation for node-positive disease, the KATHERINE trial using T-DM1 for residual disease post-neoadjuvant therapy shifted the paradigm toward using neoadjuvant response to tailor adjuvant therapy, making upfront adjuvant pertuzumab decisions heavily dependent on initial staging versus neoadjuvant approaches.

Attending

In an era increasingly focused on treatment de-escalation for early-stage breast cancer such as the APT trial, how does the APHINITY trial's strategy of treatment escalation challenge our framework for minimizing patient harm while maximizing survival?

Key Response

Attendings must balance opposing paradigms of escalation for high-risk patients and de-escalation using paclitaxel and trastuzumab for low-risk, node-negative patients. The key teaching point is that HER2-positive breast cancer is biologically heterogeneous, making precise risk stratification using nodal status essential to avoid overtreatment and unnecessary mucosal toxicity.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The APHINITY trial required a massive sample size of over 4,800 patients and an event-driven design to detect a statistically significant difference in iDFS. What are the methodological implications of powering trials for marginal absolute differences in populations with excellent baseline prognoses, and how might alternative statistical designs improve trial efficiency?

Key Response

As standard-of-care outcomes improve, proving superiority requires exceptionally large cohorts and long follow-up, raising concerns about resource allocation and the clinical relevance of the hazard ratio. Researchers must consider whether novel intermediate endpoints like ctDNA clearance or Bayesian adaptive designs could more efficiently answer these questions.

Journal Editor

A critical reviewer might note that while the primary endpoint of iDFS was met, there was no overall survival benefit at the time of publication, and the absolute iDFS difference was less than 1 percent overall. How should a journal balance the publication of statistically significant but clinically marginal results to prevent therapeutic creep?

Key Response

Editors must heavily scrutinize the clinical meaningfulness of a trial's primary endpoint. For APHINITY, the marginal absolute benefit, driven almost entirely by one subgroup, raises concerns about the clinical utility of the overall trial claim. Rigorous editorial review mandates strict highlighting of absolute risk reduction and subgroup-specific findings in the abstract.

Guideline Committee

Given the APHINITY findings, how should clinical practice guidelines like ASCO and NCCN adapt their recommendations regarding dual HER2 blockade in the adjuvant setting, specifically concerning the node-negative population?

Key Response

Guidelines must translate this evidence into actionable, stratified recommendations. NCCN and ASCO guidelines were updated to incorporate adjuvant pertuzumab as a Category 1 strong recommendation specifically for patients with node-positive HER2-positive breast cancer. For node-negative patients, guidelines appropriately recommend against routine use of dual blockade due to the lack of iDFS benefit in APHINITY.

Clinical Landscape

Noteworthy Related Trials

2005

HERA Trial

n = 5,102 · NEJM

Tested

Adjuvant trastuzumab for 1 year

Population

Women with early-stage HER2-positive breast cancer

Comparator

Observation

Endpoint

Disease-free survival (DFS)

Key result: One year of adjuvant trastuzumab significantly improved disease-free survival and overall survival compared to observation.

2012

CLEOPATRA Trial

n = 808 · NEJM

Tested

Pertuzumab plus trastuzumab and docetaxel

Population

Patients with HER2-positive metastatic breast cancer

Comparator

Placebo plus trastuzumab and docetaxel

Endpoint

Progression-free survival (PFS)

Key result: Adding pertuzumab to trastuzumab and chemotherapy significantly prolonged progression-free and overall survival in metastatic disease.

2012

NeoSphere Trial

n = 417 · Lancet Oncol

Tested

Neoadjuvant pertuzumab plus trastuzumab and docetaxel

Population

Patients with early or locally advanced HER2-positive breast cancer

Comparator

Neoadjuvant trastuzumab and docetaxel

Endpoint

Pathological complete response (pCR)

Key result: Dual HER2 blockade with pertuzumab and trastuzumab plus chemotherapy significantly increased pathological complete response rates compared to trastuzumab and chemotherapy alone.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis